XEN gel stent is Safe and Efficacious in open-angle glaucoma
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to assess the 3-year effectiveness and safety of the XEN gel stent implanted ab interno in open-angle glaucoma (OAG).

This study was a multicentre, retrospective chart review of consecutive patients with OAG who underwent ab-interno gel stent placement alone or combined with phacoemulsification. Outcome measures included mean changes in intraocular pressure (IOP) and IOP lowering medication count from medicated baseline at 1, 2, 3 (primary outcome) and 4 years (if available) postimplantation. Intraoperative complications, adverse events of special interest (AESIs) and secondary surgical interventions (SSIs) were recorded.

--The safety and effectiveness populations included 212 eyes and 174 eyes, respectively.

--Mean IOP and medication decreased from 20.7 mmHg and 2.5 at baseline (n = 163 primary/first implanted eyes) to 13.9 mmHg and 1.1 medications (n = 76) at 3 years postimplantation, respectively.

--Mean changes from baseline in IOP (-5.6, -6.2 and -6.6 mmHg) and IOP lowering medication count (-1.8, -1.6 and -1.4) were statistically significant at 1, 2 and 3 years postimplantation, respectively.

--Results appeared comparable when implantation was performed with (n = 76) or without (n = 98) phacoemulsification.

--In primary eyes with 4 year IOP and medication count data (n = 27), mean IOP was 14.0 mmHg on 1.3 medications at 4 years postimplantation.

--15 eyes had intraoperative complications, 31 experienced 46 postoperative AESIs, and 26 required SSI.

In conclusion, when implanted via the conventional abinterno method, the gel stent effectively reduced IOP and IOP lowering drug count over 3 years, with a predictable and appropriate safety profile.

Source: https://onlinelibrary.wiley.com/doi/10.1111/aos.14886?af=R